MRI与CEUS LI-RADS鉴别高危患者肝细胞癌与其他肝脏恶性肿瘤的比较
回顾性连续纳入106例高危肝细胞癌患者和52例其他肝脏恶性肿瘤患者,均行MRI和CEUS并以组织学为参考标准,比较两者LI-RADS的鉴别效能。LR-M分类准确率在MR与CEUS间无显著差异(85.4% vs 88.6%,p=0.724);修改版CEUS LI-RADS的LR-M准确率显著高于MR LI-RADS(96.8% vs 85.4%,p=0.04)。
要点
- MR与CEUS LI-RADS的LR-M分类准确率无显著差异(85.4% vs 88.6%,p=0.724)。
- MR LI-RADS诊断其他肝脏恶性肿瘤的LR-M敏感度90.4%、特异度83.0%。
- CEUS LI-RADS诊断其他肝脏恶性肿瘤的LR-M敏感度98.1%、特异度84.0%。
关键影像表现/征象
- MRI特征在其他肝脏恶性肿瘤与肝细胞癌患者间显著不同(p<0.05)。
- CEUS特征在其他肝脏恶性肿瘤与肝细胞癌患者间亦显著不同(p<0.05)。
诊断标准与关键数值
- MR LI-RADS诊断其他肝脏恶性肿瘤:各征象敏感度34.6%–69.2%、特异度83.0%–95.3%;LR-M(明确或可能恶性、非肝细胞癌特异)敏感度90.4%、特异度83.0%。
- CEUS LI-RADS诊断其他肝脏恶性肿瘤:各征象敏感度11.5%–96.2%、特异度23.6%–100%;LR-M敏感度98.1%、特异度84.0%。
- LR-M分类准确率:MR LI-RADS 85.4% vs CEUS LI-RADS 88.6%,两者无显著差异(p=0.724)。
- 修改版CEUS LI-RADS将具有清晰瘤内无强化区边界且5分钟前无穿凿样表现的LR-M结节重新归类为LR-5后,CEUS LR-M准确率从88.6%升至96.8%,CEUS LR-5准确率从84.8%升至91.1%。
- 修改版CEUS LI-RADS的LR-M准确率显著高于MR LI-RADS(96.8% vs 85.4%,p=0.04)。
临床应用与阅片要点
- 在高危患者中可用CEUS LI-RADS或MR LI-RADS的LR-M分类提示其他肝脏恶性肿瘤而非肝细胞癌。
- 作者提出,采用修改版CEUS LI-RADS(LR-M病灶具清晰瘤内无强化区边界且5分钟内无穿凿样表现时归为LR-5)可能进一步提高分类效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Distinguishing between other hepatic malignancies (OMs) and hepatocellular carcinoma (HCC) is vital to allow clinicians to determine optimal treatment and assess prognosis in patients at high risk for HCC. This study evaluated the performance of the Liver Imaging Reporting and Data System (LI-RADS) using magnetic resonance imaging (MRI) versus contrast-enhanced ultrasonography (CEUS) for differentiating HCC from OMs in patients at high risk for HCC. This retrospective study consecutively enrolled 106 high-risk patients with HCC and 52 high-risk patients with OMs. Patients underwent both MRI and CEUS, with histologic diagnosis as a reference standard. The diagnostic performance of MR versus CEUS LI-RADS was calculated and compared. The performance of the modified CEUS LI-RADS criteria was also evaluated and compared. Our research found that MRI features significantly differed between patients with OMs and those with HCC (p < 0.05), with sensitivities of 34.6%-69.2% and specificities of 83.0%-95.3% for diagnosing OMs and an LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma sensitivity of 90.4% and specificity of 83.0% for diagnosing OM. CEUS features also significantly differed between patients with OM and HCC (p < 0.05), with sensitivities of 11.5%-96.2% and specificities of 23.6%-100% for diagnosing OMs, and an LR-M sensitivity of 98.1% and specificity of 84.0% for diagnosing OMs. Accuracies of category LR-M did not significantly differ between MR and CEUS LI-RADS (85.4% vs. 88.6%, p = 0.724). After reclassification of category LR-M nodules to category LR-5 if they exhibited clear intratumoral non-enhanced area boundaries and no punched-out appearance before 5 min, accuracy increased from 88.6% to 96.8% for CEUS LR-M and from 84.8% to 91.1% for CEUS LR-5. LR-M accuracies were significantly higher for the modified version of the CEUS LI-RADS than for MR LI-RADS (96.8% vs. 85.4%, respectively, p = 0.04). CEUS LI-RADS and MR LI-RADS can effectively be used to distinguish HCC from OMs. In patients at high risk of HCC, performance may be further improved by using a modified CEUS LI-RADS classification system in which category LR-M lesions are considered LR-5 if they have clear intratumoral non-enhanced area boundaries and do not have a punched-out appearance.
引用
- Huang Z, Zhou P, Li S, et al. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients. Ultrasound Med Biol. 2021. PMID: 33610338. doi:10.1016/j.ultrasmedbio.2021.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。